ArticleBlood cancer journal2023
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.Blood advances · 2026Observational
- Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myeloma.Blood neoplasia · 2026Article
- Fiber: A New Myeloma Prevention Approach with Abundant Positive Effects.Cancer discovery · 2026Article
- Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions.Blood cancer journal · 2026Article
- Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.Blood advances · 2026Article
- Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma.Diagnostics (Basel, Switzerland) · 2025Article
- AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.Scientific reports · 2025Article
- Impact of obesity on cancer therapy outcomes: a multicenter cohort study of 30-day mortality and morbidity.Anti-cancer drugs · 2025Article
- Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.British journal of haematology · 2025Article
- Adipocytes and metabolism: Contributions to multiple myeloma.Journal of bone oncology · 2024Article
- Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.JMIR research protocols · 2024Article
- Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.Blood advances · 2024Article
- The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease.Frontiers in oncology · 2024Review
- Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Urvi A ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. shahu@mskcc.org.ORCID 0000-0001-8419-1091
Karissa WhitingDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, 1275 York Avenue, New York, NY, 10065, USA.
Sean DevlinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, 1275 York Avenue, New York, NY, 10065, USA.
Rachel ErshlerDivision of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, 5901-B Ammendale Road, Beltsville, MD, 20705-1266, USA.
Bindu KanapuruDivision of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, 5901-B Ammendale Road, Beltsville, MD, 20705-1266, USA.
David J LeeDepartment of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Sabrin TahriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Thomas GwiseDivision of Biometrics IX, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 5901-B Ammendale Road, Beltsville, MD, 20705-1266, USA.
Even H RustadDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379, Oslo, Norway.
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.ORCID 0000-0002-2815-9561
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Dickran KazandjianDepartment of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Francesco MauraDepartment of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami, 1475 NW 12th Avenue, Miami, FL, 33136, USA.ORCID 0000-0002-5017-1620
Daniel AuclairMultiple Myeloma Research Foundation, 383 Main Avenue #5, Norwalk, CT, 06851, USA.
Brenda M BirmannChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA, 02115, USA.ORCID 0000-0002-7550-5498
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Nicole GormleyDivision of Hematologic Malignancies II, Center for Drug Evaluation and Research, U.S. Food, and Drug Administration, 5901-B Ammendale Road, Beltsville, MD, 20705-1266, USA.
Catherine R Marinac *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID 0000-0002-9128-3012
Ola Landgren *Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami, 1475 NW 12th Avenue, Miami, FL, 33136, USA.ORCID 0000-0001-6485-4839
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MTransdisciplinary Research in Energetics and Cancer (TREC) Training GrantR25CA203650 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2016 to 2025
$2.9MRepurposing Metformin for the Prevention of Disease Progression in Precursor Multiple MyelomaK22CA251648 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2020 to 2022
$577kProlonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple MyelomaR21CA256644 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2022 to 2023
$453kObesity, Molecular Biomarkers, and Multiple Myeloma PrognosisF32CA220859 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2018 to 2019
$94kNCI NIH HHS F32 CA220859NCI NIH HHS K12 CA184746NCI NIH HHS K22 CA251648NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R21 CA256644NCI NIH HHS R25 CA203650
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaBody Mass IndexBortezomibHumansTreatment OutcomeBortezomib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.